Key Points
- Omnicell EVP Corey Manley sold 6,106 shares on January 8 at an average price of $49.90 for total proceeds of $304,689, reducing his stake by 6.24% to 91,674 shares (≈$4.57M).
- Analyst views are mixed: KeyCorp recently upgraded Omnicell to overweight with a $60 target, but the consensus rating is a Hold with an average target of $47.83.
- The stock is trading near its 52-week high (~$51.19 vs. $51.30), has a market cap of about $2.3B and a high trailing PE of 119.05, and is largely held by institutions (≈97.7% ownership).
Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) EVP Corey Manley sold 6,106 shares of Omnicell stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total transaction of $304,689.40. Following the completion of the transaction, the executive vice president directly owned 91,674 shares in the company, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Omnicell Stock Up 0.9%
Shares of NASDAQ:OMCL opened at $51.19 on Tuesday. The firm has a 50 day simple moving average of $41.42 and a 200 day simple moving average of $34.48. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $51.30. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.21 and a current ratio of 1.44. The company has a market cap of $2.30 billion, a PE ratio of 119.05, a price-to-earnings-growth ratio of 5.40 and a beta of 0.77.
Wall Street Analysts Forecast Growth
OMCL has been the topic of several recent analyst reports. KeyCorp raised Omnicell from a "sector weight" rating to an "overweight" rating and set a $60.00 price target on the stock in a research report on Wednesday, January 7th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Omnicell in a research note on Wednesday, October 8th. Benchmark increased their price target on shares of Omnicell from $45.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday, December 9th. Wells Fargo & Company raised their price target on shares of Omnicell from $43.00 to $52.00 and gave the stock an "overweight" rating in a report on Monday, January 5th. Finally, Zacks Research lowered shares of Omnicell from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 9th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $47.83.
View Our Latest Stock Report on OMCL
Institutional Investors Weigh In On Omnicell
Large investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its holdings in Omnicell by 9.1% in the third quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company's stock worth $71,985,000 after buying an additional 197,462 shares during the last quarter. Lazard Asset Management LLC grew its position in Omnicell by 3.8% in the second quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company's stock worth $50,225,000 after acquiring an additional 62,733 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Omnicell by 1.3% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,423,604 shares of the company's stock worth $41,854,000 after purchasing an additional 17,680 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Omnicell by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 1,195,896 shares of the company's stock valued at $35,163,000 after purchasing an additional 30,678 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Omnicell in the 3rd quarter valued at $25,625,000. Institutional investors own 97.70% of the company's stock.
About Omnicell
(
Get Free Report)
Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.
Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
